Modeling phenotypes of malignant gliomas

被引:15
|
作者
Sampetrean, Oltea [1 ]
Saya, Hideyuki [1 ]
机构
[1] Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat,Shinjuku Ku, Keio, Japan
关键词
experimental model; genetically engineered mouse model; glioma cell of origin; glioma invasion; malignant glioma; GROWTH-FACTOR RECEPTOR; NEURAL STEM-CELL; MOSAIC ANALYSIS; DOUBLE MARKERS; MOUSE MODELS; BRAIN-TUMORS; GLIOBLASTOMA; ACTIVATION; MIGRATION; INVASION;
D O I
10.1111/cas.13351
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Malignant gliomas are primary tumors of the central nervous system characterized by diffuse infiltration into the brain and a high recurrence rate. Advances in comprehensive genomic studies have provided unprecedented insight into the genetic and molecular heterogeneity of these tumors and refined our understanding of their evolution from low to high grade. However, similar levels of phenotypic characterization are indispensable to understanding the complexity of malignant gliomas. Experimental glioma models have also achieved great progress in recent years. Advances in transgenic technologies and cell culture have allowed the establishment of mouse models that mirror the human disease with increasing fidelity and which support single-cell resolution for phenotypic analyses. Here we review the major types of preclinical glioma models, with an emphasis on how recent developments in experimental modeling have shed new light on two fundamental aspects of glioma phenotype, their cell of origin and their invasive potential.
引用
收藏
页码:6 / 14
页数:9
相关论文
共 50 条
  • [1] Experimental approaches for the treatment of malignant gliomas
    Arko, Leopold
    Katsyv, Igor
    Park, Grace E.
    Luan, William Patrick
    Park, John K.
    PHARMACOLOGY & THERAPEUTICS, 2010, 128 (01) : 1 - 36
  • [2] Inhibition of angiogenesis and invasion in malignant gliomas
    Chi, Andrew
    Norden, Andrew D.
    Wen, Patrick Y.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (11) : 1537 - 1560
  • [3] Molecularly targeted therapies for malignant gliomas: advances and challenges
    Penas-Prodo, Marto
    Gilbert, Mork R.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (05) : 641 - 661
  • [4] Antiangiogenic therapy in malignant gliomas
    Norden, Andrew D.
    Drappatz, Jan
    Wen, Patrick Y.
    CURRENT OPINION IN ONCOLOGY, 2008, 20 (06) : 652 - 661
  • [5] Malignant Gliomas: Current Concepts
    Lee, Ian Y.
    Kalkanis, Steven N.
    Rosenblum, Mark L.
    NEUROSURGERY QUARTERLY, 2010, 20 (03) : 115 - 121
  • [6] Chemotherapy in the treatment of malignant gliomas
    Stem, Jennifer I.
    Raizer, Jeffrey J.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2006, 6 (05) : 755 - 767
  • [7] Tumor Vaccines for Malignant Gliomas
    Srinivasan, Visish M.
    Ferguson, Sherise D.
    Lee, Sungho
    Weathers, Shiao-Pei
    Kerrigan, Brittany C. Parker
    Heimberger, Amy B.
    NEUROTHERAPEUTICS, 2017, 14 (02) : 345 - 357
  • [8] Nimotuzumab treatment of malignant gliomas
    Bode, Udo
    Massimino, Maura
    Bach, Ferdinand
    Zimmermann, Martina
    Khuhlaeva, Elena
    Westphal, Manfred
    Fleischhack, Gudrun
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (12) : 1649 - 1659
  • [9] Quantifying the Role of Angiogenesis in Malignant Progression of Gliomas: In Silico Modeling Integrates Imaging and Histology
    Swanson, Kristin R.
    Rockne, Russell C.
    Claridge, Jonathan
    Chaplain, Mark A.
    Alvord, Ellsworth C., Jr.
    Anderson, Alexander R. A.
    CANCER RESEARCH, 2011, 71 (24) : 7366 - 7375
  • [10] Quantifying the role of immunotherapeutic drug T11 target structure in progression of malignant gliomas: Mathematical modeling and dynamical perspective
    Khajanchi, Subhas
    Banerjee, Sandip
    MATHEMATICAL BIOSCIENCES, 2017, 289 : 69 - 77